Development of siRNA payloads to target KRAS-Mutant cancer Journal Article


Authors: Yuan, T. L.; Fellmann, C.; Lee, C. S.; Ritchie, C. D.; Thapar, V.; Lee, L. C.; Hsu, D. J.; Grace, D.; Carver, J. O.; Zuber, J.; Luo, J.; McCormick, F.; Lowe, S. W.
Article Title: Development of siRNA payloads to target KRAS-Mutant cancer
Abstract: RNAi is a powerful tool for target identification and can lead to novel therapies for pharmacologically intractable targets such as KRAS. RNAi therapy must combine potent siRNA payloads with reliable in vivo delivery for efficient target inhibition. We used a functional “Sensor” assay to establish a library of potent siRNAs against RAS pathway genes and to show that they efficiently suppress their targets at low dose. This reduces off-target effects and enables combination gene knockdown. We administered Sensor siRNAs in vitro and in vivo and validated the delivery of KRAS siRNA alone and siRNA targeting the complete RAF effector node (A/B/CRAF) as promising strategies to treat KRAS -mutant colorectal cancer. We further demonstrate that improved therapeutic efficacy is achieved by formulating siRNA payloads that combine both single-gene siRNA and node-targeted siRNAs (KRAS + PIK3CA/B). The customizable nature of Sensor siRNA payloads offers a universal platform for the combination target identification and development of RNAi therapeutics.
Journal Title: Cancer Discovery
Volume: 4
Issue: 10
ISSN: 2159-8274
Publisher: American Association for Cancer Research  
Date Published: 2014-10-01
Start Page: 1182
End Page: 1197
Language: English
DOI: 10.1158/2159-8290.cd-13-0900
PROVIDER: scopus
PMCID: PMC4184972
PUBMED: 25100204
DOI/URL:
Notes: Export Date: 3 November 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Scott W Lowe
    249 Lowe
  2. Danielle M. Grace
    2 Grace
  3. Vishal Thapar
    5 Thapar